arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

bioAffinity Technologies, Inc.

BIAF
$2.65 ▼ -0.38 (-12.42%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
23 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

bioAffinity Technologies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.9M
Dividend Yield —
Revenue Growth 19.0% ↗
Op. Margin -220.8% ↗
ROIC -69.9% ↗
FCF / Share $-0.63 ↗
Trailing P/E —
Price / Book 4.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.51M
↑ +19.0% —
Net Income Profit after all expenses
$-3.37M
↑ +17.1% —
Operating Margin Operating profit as % of sales
-220.8%
↑ +17.5% 1th
FCF / Share Free cash flow per share
$-0.63
↑ +12.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
2
Financial Health ↓
50
Cash Quality ↑
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 23 quarters